Pair of Lancet studies give final word on a promising Shionogi antibiotic that turned out to be 'as good' as the other 'suboptimal' options
Last October, the FDA OK’d a semi-controversial new antibiotic from Shionogi.
In one of two large studies for the drug, known chemically as cefiderocol …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
